期刊文献+

组织蛋白酶-B、组织蛋白酶-L及尿激酶类纤溶酶原激活剂在非霍奇金淋巴瘤中的表达及其意义

Expression of cathepsin B, cathepsin L and uPA mRNA levels in non-Hodgkin lymphoma and their significance
原文传递
导出
摘要 目的 探讨组织蛋白酶-B(CTS-B)、组织蛋白酶-L(CTS-L)及尿激酶类纤溶酶原激活剂(uPA)在非霍奇金淋巴瘤(NHL)中的表达,分析三者间及与临床病理因素间的相关性.方法 选取未经化疗或放疗的NHL患者39例,以淋巴结反应性增生15例作为对照.采用实时荧光定量反转录聚合酶链反应(PCR)法检测淋巴结肿瘤组织CTS-B、CTS-L及uPA mRNA的相对表达水平.分析三者的表达变化及与临床病理因素间的相关性.结果 CTS-B、CTS-L、uPA mRNA在NHL患者中表达水平明显高于对照组(0.403比0.128、0.209比0.057、0.459比0.031,均P<0.05),且三者间存在相关性.CTS-B、CTS-L、uPA mRNA在晚期NHL组中表达水平高于早期组(0.453比0.341、0.204比0.085、0.372比0.196,均P<0.05),CTS-B、CTS-L、uPA mRNA在NHL化疗敏感组中的相对表达水平低于化疗耐受组(0.401比0.556、0.085比0.205、0.316比0.499,均P<0.05).结论 CTS-B、CTS-L、uPA在NHL中高表达,与NHL的生物学行为密切相关;NHL患者CTS-B、CTS-L及uPA的联合检测及动态观察可作为NHL临床辅助诊断及预后判断的指标之一. Objective To investigate mRNA expression levels of cathepsin B,cathepsin L and uPA in non-Hodgkin lymphoma (NHL) samples,and analyze the relationship between three genes and clinicopathological factors.Methods Real-time fluorescence quantitative RT-PCR was used to quantify the relative expression levels of cathepsin B,cathepsin L and uPA mRNA in 39 NHL patients without chemotherapy or radiotherapy and 15 patients with lymph node reactive hyperplasia.Relationship between their expression and clinico-pathological factors was analyzed.Results mRNA expression levels of cathepsin B,cathepsin L and uPA in NHL group were significantly higher than those in the control group (0.403 vs 0.128,0.209 vs 0.057,0.459 vs 0.031,all P 〈 0.05).The mRNA expression levels of cathepsin B,cathepsin L and uPA were correlated with each other in NHL.The mRNA expression levels of cathepsin B,cathepsin L and uPA in advanced staged NHL were markedly higher than those in early staged NHL (0.453 vs 0.341,0.204 vs 0.085,0.372 vs 0.196,all P 〈 0.05).mRNA levels of cathepsin B,cathepsin L and uPA were higher in NHL patients sensitive to chemotherapy than in those resistant to chemotherapy(0.401 vs 0.556,0.085 vs 0.205,0.316 vs 0.499,all P 〈 0.05).Conclusions The high expression of cathepsin B,cathepsin L and uPA could be detected in NHL,and their expression has a close relationship with the biological behavior characters of NHL.The dynamic examination of cathepsin B,cathepsin L and uPA may be used as clinical auxiliary diagnosis and prognosis of NHL.
出处 《白血病.淋巴瘤》 CAS 2014年第7期401-404,共4页 Journal of Leukemia & Lymphoma
关键词 淋巴瘤 非霍奇金 组织蛋白酶B 组织蛋白酶L 尿激酶型纤溶酶原激活剂 预后 Lymphoma, non-Hodgkin Cathepsin B Cathepsin L Urokinase-type plasminogen activator Prognosis
  • 相关文献

参考文献16

  • 1Grillo López AJ,Cheson BD,Homing SJ,et al.Response criteria for NHL:important of normal lymph node size and correlations with response rates[J].Ann Oncol,2000,11:399-408.
  • 2Patani N,Martin LA,Dowsett M.Biomarkers for the clinical management of breast cancer:international perspective[J].Int J Cancer,2013,133:1-13.
  • 3王虹虹,牛义凯,张英凯.血浆尿激酶型纤溶酶原激活系统与肿瘤标志物联合检测非小细胞肺癌的临床价值[J].肿瘤研究与临床,2012,24(6):420-422. 被引量:1
  • 4Zhang W,Ling D,Tan J,et al.Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance[J].Oncol Rep,2013,29:637-645.
  • 5姜建涛,周斌,张淑群,李少民,张潍,张晋,乔哲,孔冉冉,马跃峰.尿纤溶酶原激活物及血管内皮生长因子在食管癌中的表达及对肿瘤血管形成的影响[J].肿瘤研究与临床,2011,23(6):372-375. 被引量:1
  • 6张克俭,张丽,何莉,左学兰,陈飞.PAI-1、u-PA、VEGF在非霍奇金淋巴瘤中的表达及临床意义[J].武汉大学学报(医学版),2009,30(4):477-480. 被引量:4
  • 7Gondi CS,Rao JS.Cathepsin B as a cancer target[J].Expert Opin Ther Targets,2013,17:281-291.
  • 8Reiser J,Adair B,Reinhecki T.Specialized roles for cysteine cathepsins in health and disease[J].J Clin Invest,2010,120:3421-3431.
  • 9Gogineni VR,Gupta R,Nalla AK,et al.uPAR and cathepsin B shRNA impedes TGF-β 1-driven proliferation and invasion of meningioma cells in a XIAP-dependent pathway[J].Cell Death Dis,2012,6:e439.
  • 10Gong F,Peng X,Luo C,et al.Cathepsin B as a potential prognostic and therapeutic marker for human lung squamous cell carcinoma[J].Mol Cancer,2013,12:125.

二级参考文献38

  • 1秦蓉,盛霞,吴继锋,王道斌.胃癌组织中uPA系统及VEGF表达与侵袭转移的关系[J].世界华人消化杂志,2005,13(6):706-710. 被引量:7
  • 2牛义凯,肖伟,朱媛媛.肺癌患者血浆尿激酶型纤溶酶原激活系统的研究[J].中国肺癌杂志,2006,9(4):369-372. 被引量:3
  • 3肖继平,张莉,齐云,龚攀.uPA及VEGF在乳腺癌中的表达及意义[J].中国普通外科杂志,2007,16(1):93-96. 被引量:15
  • 4Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost, 1997, 78: 285-296.
  • 5Katoh Y, Katoh M. Comparative integromics on VEGF family members. Int J Oncol, 2006, 28: 1585-1589.
  • 6Iseki K, Tatsuata M, Uehara H, et al. Inhibitor of angiogenesis as a mechanism for inhibitor by 1 α-hydroxyvitamin D3 and 1,25- dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rat. Int Cancer, 1999, 81: 730-733.
  • 7Bosari S, Lee AK, Delellis RA, et al. Microvessel quantitation and prognosis in invasive breast carcinoma.Hum Pathol, 1992, 23: 755- 761.
  • 8Mazar AP. Urokinase plasminogen activator receptor choreographs multiple ligand interactions:implications for tumor progression and therapy. Clin Cancer Res, 2008, 14: 5649-5655.
  • 9Zhang QX, Magovem C J, Mack CA, et al. Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res, 1997, 67: 147-154.
  • 10Conn EM, Botkjaer KA, Kupriyanova TA, et al. Comparative analysis of metastasis variants derived from human prostate carcinoma eeUs. Am J Pathol, 2009, 175: 1638-1652.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部